Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17417552 | 0.88 | PTGER4 (0.37) | CYP1A2CTSLCTSBMAPTSMN1; SMN2 | |
| SCHEMBL19584784 | 0.85 | CYP1A2 (0.51) | CYP1A2MAPTGABRA2GABRB2ALDH1A1 | |
| SCHEMBL17417363 | 0.77 | PTGER4 (0.39) | CYP1A2MAPTSMN1; SMN2TP53NPC1 | |
| SCHEMBL17429955 | 0.75 | TLR8 (0.35) | GRM5 | |
| SCHEMBL19584461 | 0.73 | CYP1A2 (0.57) | CYP1A2MAPTGABRA2GABRB2ALDH1A1 | |
| SCHEMBL14770747 | 0.68 | CTSL (0.40) | CYP1A2CTSLCTSBMAPTGABRA2 | |
| SCHEMBL6708132 | 0.67 | CA1 (0.54) | CYP1A2MAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3328822 | 0.67 | CYP1A2 (0.49) | CYP1A2MAPTGABRA2GABRB2ALDH1A1 | |
| SCHEMBL1695597 | 0.67 | CYP1A2 (0.49) | CYP1A2MAPTGABRA2ALDH1A1SMN1; SMN2 | |
| SCHEMBL16415870 | 0.66 | CYP1A2 (0.77) | CYP1A2MAPTTRPM8GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3455212-B1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | HEPTARES THERAPEUTICS LTD (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-10995072-B2 | Inhibitors of protease-activated receptor-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-05-04 | — | — | US | disclosed |
| US-20200140392-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | NXERA PHARMA UK LIMITED (GB) | 2020-05-07 | — | — | US | disclosed |
| US-10550089-B2 | Inhibitors of protease-activated receptor-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-02-04 | — | — | US | disclosed |
| US-20190144394-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-05-16 | — | — | US | disclosed |
| EP-3455212-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | Heptares Therapeutics Limited (GB) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017194716-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | ASTRAZENECA AB (SE) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550089-B2 | Inhibitors of protease-activated receptor-2 | F2RL1, F2R, F2RL3 | CYP1A2 474/4885CTSL 73/4885CTSB 35/4885 |
| US-20190144394-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | F2RL1, F2R, F2RL3 | CYP1A2 474/4885CTSL 73/4885CTSB 35/4885 |
| US-10995072-B2 | Inhibitors of protease-activated receptor-2 | F2RL1, F2R, F2RL3 | CYP1A2 963/4885CTSL 66/4885CTSB 30/4885 |
| US-20200140392-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | F2RL1, F2R, F2RL3 | CYP1A2 963/4885CTSL 66/4885CTSB 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.